Friday, August 24, 2018 10:22:49 PM
1) Admit that JNJ is moving forward with the deal and the job posting was probably not the best way to let the cat out of the bag. After they revive their chief counsel, they will have almost as much explaining to do as Elon Musk for his 'Fully Funded' comment. Not a good strategy.
2) Dummy up and say nothing or 'no comment'. That implies choice #1 without explicitly saying so. That's also a non-starter.
3) Make something up about how it was a prototype job spec written by some low level underling or better yet, some summer intern, based on all the new drugs in the pipeline without regard to acquisition status. Sounds like a dumb move on someone's part, but plausible. Someone will get reamed for it, but it's an honest mistake and now they have to deny it to fix it. So that's what they did.
The facts remain that either their HR department has a lot of turnover and people don't understand the severity of this action or someone forgot to review the copy before posting. I think the job posting was meant to happen 30 days from now and someone decided to move up the date. They neglected to read the copy before issuing the post and this mistake was published. But that's just my assessment of the situation.
Recent GERN News
- Form 8-K - Current report • Edgar (US Regulatory) • 01/13/2025 01:05:16 PM
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 01/10/2025 09:05:52 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/02/2025 09:05:13 PM
- Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) • Business Wire • 12/19/2024 09:30:00 PM
- Geron Announces Positive CHMP Opinion for RYTELO™ (imetelstat) for the Treatment of Adults with Transfusion-Dependent Anemia due to Lower-Risk MDS • Business Wire • 12/13/2024 11:36:00 AM
- Geron Announces Phase 1 Findings from Two-Part IMproveMF Study Presented at ASH Suggesting Tolerability of RYTELO™ (imetelstat) in Combination with Ruxolitinib as Frontline Therapy in Patients with Myelofibrosis • Business Wire • 12/10/2024 02:00:00 PM
- Geron Announces New IMerge Analyses Presented at ASH Suggesting Clinical Activity of RYTELO™ (imetelstat) in Patients with Lower-Risk MDS Regardless of Type or Number of Prior Therapies • Business Wire • 12/10/2024 02:00:00 PM
- Geron to Participate in the 7th Annual Evercore ISI HealthCONx Conference • Business Wire • 11/27/2024 02:00:00 PM
- Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) • Business Wire • 11/21/2024 09:30:00 PM
- Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend] • Edgar (US Regulatory) • 11/14/2024 02:31:41 PM
- Form SC 13G - Statement of Beneficial Ownership by Certain Investors • Edgar (US Regulatory) • 11/14/2024 11:25:29 AM
- Geron Corporation Announces Appointment of Joseph Eid, M.D. as Executive Vice President, Research and Development • Business Wire • 11/11/2024 09:30:00 PM
- Geron to Participate in the Stifel 2024 Healthcare Conference • Business Wire • 11/11/2024 02:00:00 PM
- Royalty Pharma to Acquire Royalty Interest in Geron’s RYTELO for $125 Million • GlobeNewswire Inc. • 11/07/2024 12:10:00 PM
- Geron Corporation Announces Up to $375 Million in Funding with Royalty Pharma and Pharmakon Advisors • Business Wire • 11/07/2024 12:01:00 PM
- Geron Corporation Reports Third Quarter 2024 Financial Results and Recent Business Highlights • Business Wire • 11/07/2024 12:00:00 PM
- Geron Announces New Data to be Presented at Upcoming ASH Annual Meeting Highlighting the Potential of RYTELO™ (imetelstat) in Myeloid Hematologic Malignancies • Business Wire • 11/05/2024 02:00:00 PM
- Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) • Business Wire • 10/17/2024 08:30:00 PM
- Geron to Announce Third Quarter 2024 Financial Results on November 7, 2024 • Business Wire • 10/15/2024 08:30:00 PM
- Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) • Business Wire • 09/19/2024 08:30:00 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 09/09/2024 08:35:06 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/09/2024 08:35:03 PM
- Geron Corporation Announces Appointment of Jim Ziegler as Chief Commercial Officer • Business Wire • 09/09/2024 08:15:00 PM
- Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) • Business Wire • 08/22/2024 08:30:00 PM
- Geron Corporation Reports Second Quarter 2024 Financial Results and Business Highlights • Business Wire • 08/08/2024 11:00:00 AM
Good Gaming Inc. Announces ViaOne Services' Intent to Purchase Up to 10% of Its Common Shares in the Open Market • GMER • Jan 16, 2025 8:30 AM
Avant Technologies and Ainnova Begin Implementing and Testing Advanced AI Algorithms for Early Detection of Additional Diseases • AVAI • Jan 16, 2025 8:00 AM
VOCODIA HOLDINGS INC. (OTCMKTS: VHAI) and TRACCOM INC. (OTCMKTS: TRCC) have signed an MOU to form a Joint Venture that will Revolutionize Event Monitoring with Narrative AI • VHAI • Jan 15, 2025 2:53 PM
UAV Corp (OTC: UMAV) Engages Legal Counsel to Initiate Uplisting Process with Ultimate Goal of NASDAQ Listing • UMAV • Jan 15, 2025 8:30 AM
HealthLynked Welcomes Jeremy Daniel as Chief Financial Officer • HLYK • Jan 15, 2025 8:00 AM
Zefiro Methane Corp. Subsidiary Awarded Slate of Government of Ohio-Funded Environmental Remediation Projects • ZEFI • Jan 15, 2025 7:33 AM